These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38518871)

  • 1. Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles.
    Lu Q; Gao W; Chen Z; Liu Z; Wang J; Zeng L; Hu X; Zheng E; Zhang Q; Song H
    Int J Pharm; 2024 Apr; 655():124028. PubMed ID: 38518871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
    Dong X; Mattingly CA; Tseng MT; Cho MJ; Liu Y; Adams VR; Mumper RJ
    Cancer Res; 2009 May; 69(9):3918-26. PubMed ID: 19383919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
    Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
    Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
    Jin L; Yingchun W; Zhujun S; Yinan W; Dongchen W; Hui Y; Xi Y; Wanzhou Z; Buluan Z; Jinhua W
    Biomed Pharmacother; 2019 Aug; 116():108992. PubMed ID: 31129513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
    Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
    J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
    Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
    Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ester derivative of tenacigenin B from Marsdenia tenacissima (Roxb.) Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2.
    Wu ZL; Chen Y; Qu Z; Wu GY; He XF; Huang JW; Meng QQ; Hu YH; Shen XL; Yang RY; Hu YJ
    J Ethnopharmacol; 2022 Aug; 294():115353. PubMed ID: 35533911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency.
    Lin R; Zhang L; Ye B; Wang Y; Li YD; Jason H; Liu W; Hu P; Chen J; Chen ZS; Chen Z
    Cancer Lett; 2023 Jun; 563():216181. PubMed ID: 37086953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morin reverses P-glycoprotein-mediated multidrug-resistance in KBChR-8-5 cancer cell lines.
    Zhao Y; Xu S; Hao W; Fu Y
    Cell Biochem Funct; 2024 Jul; 42(5):e4083. PubMed ID: 38938150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells.
    Wang B; Li S; Meng X; Shang H; Guan Y
    Tumour Biol; 2015 Aug; 36(8):6433-43. PubMed ID: 25801244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quercetin overcomes colon cancer cells resistance to chemotherapy by inhibiting solute carrier family 1, member 5 transporter.
    Zhou Y; Zhang J; Wang K; Han W; Wang X; Gao M; Wang Z; Sun Y; Yan H; Zhang H; Xu X; Yang DH
    Eur J Pharmacol; 2020 Aug; 881():173185. PubMed ID: 32422185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
    Wei G; Yang G; Wei B; Wang Y; Zhou S
    Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
    Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
    Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physcion-8-O-β-d-glucoside interferes with the nuclear factor-κB pathway and downregulates P-glycoprotein expression to reduce paclitaxel resistance in ovarian cancer cells.
    Li X; He Y; Wei L; Zhang J; Li X; Cui W; Zhang S
    J Pharm Pharmacol; 2021 Mar; 73(4):545-552. PubMed ID: 33793827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo.
    Liu RM; Xu P; Chen Q; Feng SL; Xie Y
    Phytomedicine; 2020 Dec; 79():153342. PubMed ID: 32992085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.
    Chen FQ; Zhang JM; Fang XF; Yu H; Liu YL; Li H; Wang YT; Chen MW
    Acta Pharmacol Sin; 2017 Jun; 38(6):859-873. PubMed ID: 28260803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key structure of brij for overcoming multidrug resistance in cancer.
    Tang J; Wang Y; Wang D; Wang Y; Xu Z; Racette K; Liu F
    Biomacromolecules; 2013 Feb; 14(2):424-30. PubMed ID: 23311629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
    Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
    Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.